Fig. 2

Cumulative incidence curves of outcomes for diabetic AF patients taking oral anticoagulants after propensity score stabilized weighting (PSSW). Cumulative incidence curves of effectiveness outcomes including ischemic stroke/systemic embolism (IS/SE), acute myocardial infarction (AMI), and major adverse cardiovascular events (MACE) a, major adverse limb events including lower extremity revascualization procedure, lower limb amputation, and major adverse limb events (MALE) b, and safety outcomes including intracranaial hemorrhage (ICH), major gastrointestinal bleeding, and all major bleeding c for AF patients with concomiant DM taking oral anticoagulants after PSSW are presented. NOAC was associated with a lower risk of MACE, MALE, and all major bleeding events than warfarin among AF patients with concomitant DM. Abbreviations: AF atrial fibrillation, AMI acute myocardial infarction, DM diabetes mellitus, ICH intracranial hemorrhage, IS/SE ischemic stroke/systemic embolism, MACE major adverse cardiovascular events, MALE major adverse limb events, NOAC non-vitamin K antagonist oral anticoagulants, PSSW propensity score stabilized weighting